Seragon Pharmaceuticals Inc.
Blocking and depleting receptors in estrogen-dependent tumors
This article was originally published in Start Up
Seragon Pharmaceuticals Inc. spun out of Aragon Pharmaceuticals just days before J&J acquired it in 2013. Like Aragon, Seragon's mission is to develop orally active selective estrogen receptor degraders (SERDs) as treatments for cancers fueled by estrogen.